Genetic testing for breast and ovarian cancer: tackling the challenges to availability
Should all platinum sensitive patients recieve PARP inhibitors?
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer
Innovations in ovarian cancer treatment: PARP inhibitors
Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer